JP2009537143A - Ｓａｒｓコロナウイルスに対する抗体 - Google Patents

Ｓａｒｓコロナウイルスに対する抗体 Download PDF

Info

Publication number
JP2009537143A
JP2009537143A JP2009511112A JP2009511112A JP2009537143A JP 2009537143 A JP2009537143 A JP 2009537143A JP 2009511112 A JP2009511112 A JP 2009511112A JP 2009511112 A JP2009511112 A JP 2009511112A JP 2009537143 A JP2009537143 A JP 2009537143A
Authority
JP
Japan
Prior art keywords
sars
cov
antibody
protein
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537143A5 (https=
Inventor
ジョン エス． バブクック
ベルール エス． プラバカール
メリッサ コグリン
Original Assignee
アムゲン インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムゲン インコーポレイティッド filed Critical アムゲン インコーポレイティッド
Publication of JP2009537143A publication Critical patent/JP2009537143A/ja
Publication of JP2009537143A5 publication Critical patent/JP2009537143A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009511112A 2006-05-19 2007-05-21 Ｓａｒｓコロナウイルスに対する抗体 Pending JP2009537143A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80195106P 2006-05-19 2006-05-19
PCT/US2007/012136 WO2008060331A2 (en) 2006-05-19 2007-05-21 Antibodies to sars coronavirus

Publications (2)

Publication Number Publication Date
JP2009537143A true JP2009537143A (ja) 2009-10-29
JP2009537143A5 JP2009537143A5 (https=) 2010-07-15

Family

ID=39402157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511112A Pending JP2009537143A (ja) 2006-05-19 2007-05-21 Ｓａｒｓコロナウイルスに対する抗体

Country Status (7)

Country Link
US (1) US7728110B2 (https=)
EP (1) EP2035454A2 (https=)
JP (1) JP2009537143A (https=)
AU (1) AU2007320075A1 (https=)
CA (1) CA2652728A1 (https=)
MX (1) MX2008014710A (https=)
WO (1) WO2008060331A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015069A1 (ko) * 2020-07-16 2022-01-20 (주)케어젠 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드
WO2022044573A1 (ja) 2020-08-26 2022-03-03 国立大学法人熊本大学 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片
KR20220052645A (ko) * 2020-10-21 2022-04-28 재단법인 바이오나노헬스가드연구단 스트렙트아비딘 결합 펩타이드가 태그된 중증급성호흡기증후군 코로나바이러스 특이적 항원 및 이의 용도
JP2023518312A (ja) * 2020-03-22 2023-04-28 クアドルセプト バイオ リミテッド ウイルス株の進化のための多量体
JP2023536737A (ja) * 2020-08-04 2023-08-29 アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー Ｓａｒｓ－ｃｏｖ－２を検出するためのアッセイ
JP2023544910A (ja) * 2020-10-05 2023-10-25 アルピ・ロジャース コロナウイルス治療法
JP2024502347A (ja) * 2021-01-05 2024-01-18 センター フォー エクセレンス イン モレキュラー セル サイエンス，チャイニーズ アカデミー オブ サイエンシーズ 抗コロナウイルス完全ヒト広域スペクトル中和抗体７６ｅ１及びその適用
JP2025507227A (ja) * 2021-10-01 2025-03-14 エターニヴァックス バイオメディカル，インコーポレーテッド 新型コロナウイルスｓ２タンパク質のｈｒ領域に由来する組換え融合タンパク質およびその使用

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687147C (en) 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
AU2016202118B2 (en) * 2009-03-20 2017-10-26 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2012162698A1 (en) 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
US10466160B2 (en) 2011-08-01 2019-11-05 Celsee Diagnostics, Inc. System and method for retrieving and analyzing particles
CN103998394B (zh) 2011-08-01 2016-08-17 德诺弗科学公司 细胞捕获系统和使用方法
WO2013185055A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP2968548B1 (en) * 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US10391490B2 (en) 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US20190284259A1 (en) * 2016-07-22 2019-09-19 Georgia State University Research Foundation Monoclonal Antibodies to B Virus And Their Use For Identification Of B Virus Specific Reactive Peptides
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US10391492B2 (en) 2017-08-29 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
USD903413S1 (en) 2018-08-09 2020-12-01 Sharkninja Operating Llc Cooking basket
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
US10633693B1 (en) 2019-04-16 2020-04-28 Celsee Diagnostics, Inc. System and method for leakage control in a particle capture system
US11339190B2 (en) * 2020-04-21 2022-05-24 Rush University Medical Center Peptides for the treatment of covid-19
US11273439B2 (en) 2019-05-07 2022-03-15 Bio-Rad Laboratories, Inc. System and method for target material retrieval from microwells
AU2020267743B2 (en) 2019-05-07 2023-04-06 Bio-Rad Laboratories, Inc. System and method for automated single cell processing
WO2020251802A1 (en) 2019-06-14 2020-12-17 Bio-Rad Laboratories, Inc. System and method for automated single cell processing and analyses
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
TWI818236B (zh) * 2020-02-19 2023-10-11 美商聯合生物醫學公司 用於檢測、預防和治療新型冠狀病毒(covid-19)疾病的設計胜肽及蛋白質
CN112500498B (zh) * 2020-02-26 2022-09-06 四川大学 新型冠状病毒疫苗及其制备方法和应用
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
WO2021190980A1 (en) * 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
CN113429476A (zh) * 2020-03-23 2021-09-24 泰州迈博太科药业有限公司 一种结合冠状病毒的双功能融合蛋白、其制备方法及应用
CN115279785B (zh) * 2020-03-25 2025-09-05 神州细胞工程有限公司 SARS-CoV-2和SARS-CoV交叉中和抗体的制备及应用
WO2021198220A1 (en) * 2020-03-30 2021-10-07 Allero Therapeutics B.V. Treatment and prevention of secondary inflammation in patients suffering from a viral infection
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
WO2021207014A2 (en) * 2020-04-06 2021-10-14 Phylex Biosciences, Inc. Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
WO2021214467A1 (en) * 2020-04-23 2021-10-28 Cellbio A diagnostic tool improvement comprising a pathogen binding molecule
CN115916256B (zh) * 2020-04-24 2026-01-27 单细胞科技公司 抗SARS-CoV-2刺突蛋白抗体
US20230399384A1 (en) * 2020-04-24 2023-12-14 The Board Of Regents Of The University Of Texas System Antibodies to coronavirus spike protein and methods of use thereof
WO2021221493A1 (ko) * 2020-04-29 2021-11-04 한국화학연구원 사스 코로나바이러스 2 스파이크 단백질과 결합하는 수용체와 항체를 포함하는 사스 코로나바이러스 2 진단 키트
KR102351653B1 (ko) * 2020-04-29 2022-01-14 한국화학연구원 사스 코로나바이러스 2 스파이크 단백질과 결합하는 수용체와 항체를 포함하는 사스 코로나바이러스 2 진단 키트
WO2021221668A1 (en) * 2020-04-30 2021-11-04 iRepertoire, Inc. Anti-sars-cov-2 monoclonal antibody compositions
US12584917B2 (en) * 2020-05-06 2026-03-24 Academia Sinica Recombinant antibodies, kits comprising the same, and uses thereof
CN113667010B (zh) * 2020-05-15 2023-07-28 普米斯生物技术(珠海)有限公司 冠状病毒的抗体及其衍生物用途
WO2021237051A1 (en) * 2020-05-22 2021-11-25 Jecho Laboratories, Inc. SARS-CoV-2 ANTIBODY AND RELATED METHODS
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2021286655A1 (en) * 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
WO2021257695A2 (en) * 2020-06-16 2021-12-23 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
KR102662789B1 (ko) * 2020-07-01 2024-05-03 앱클론(주) 항-SARS-CoV-2 S 단백질 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 SARS-CoV-2 감염증의 예방 또는 치료용 약제학적 조성물
CN113945714B (zh) * 2020-07-16 2023-01-31 南京蓬勃生物科技有限公司 新型冠状病毒中和抗体类药物中和能力的检测方法
CN116693671A (zh) * 2020-07-20 2023-09-05 福建医科大学附属协和医院 新型冠状病毒中和性抗体及其制备方法与用途
CN113336831A (zh) * 2020-07-24 2021-09-03 上海延立药业有限公司 一种用于开发新冠病毒疫苗的长效重组糖蛋白
WO2022026775A1 (en) * 2020-07-30 2022-02-03 Prellis Biologics, Inc Compositions and methods for targeting coronavirus
CN116406274B (zh) * 2020-07-30 2026-02-17 迪赞纳生命科学公开有限公司 用于治疗冠状病毒的cd3抗体
WO2022051223A1 (en) * 2020-09-02 2022-03-10 The Feinstein Institutes For Medical Research Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
CN114159445B (zh) * 2020-09-11 2024-03-19 中国科学院分子细胞科学卓越创新中心 筛选抑制新型冠状病毒感染的小分子药物的方法及其应用
WO2022054068A1 (en) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Antibodies for the prevention, treatment and detection of coronavirus infection
EP3970798A1 (en) * 2020-09-18 2022-03-23 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Sars-cov-2-nanobodies
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
CN112442120A (zh) * 2020-11-25 2021-03-05 苏州大学 抗严重急性呼吸系统综合征ii型冠状病毒sars-cov-2的中和抗体
CN114605527B (zh) * 2020-12-04 2023-07-04 中国科学院分子细胞科学卓越创新中心 一种抗新型冠状病毒SARS-CoV-2的抗体及其制备方法和用途
WO2022127739A1 (zh) * 2020-12-14 2022-06-23 杰科（天津）生物医药有限公司 特异性结合SARS-CoV-2的抗原结合蛋白
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
WO2022156670A1 (en) * 2021-01-19 2022-07-28 Hifibio (Hk) Limited Multispecific antibodies against sars-cov-2 and methods of use thereof
WO2022159685A2 (en) * 2021-01-22 2022-07-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
CN115667506A (zh) * 2021-02-10 2023-01-31 西雅图免疫公司 重组ace2-fc融合分子及其制备和使用方法
WO2022177870A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023039064A2 (en) * 2021-09-08 2023-03-16 The Scripps Research Institute Broadly neutralizing antibodies against sars-like viruses
US20250076309A1 (en) 2021-10-05 2025-03-06 Amgen Inc. Fc-gamma receptor ii binding and glycan content
EP4466284A2 (en) * 2021-10-27 2024-11-27 Twist Bioscience Corporation Multispecific sars-cov-2 antibodies and methods of use
CN118369438A (zh) 2021-12-10 2024-07-19 伯乐实验室有限公司 用形态可调节功能化颗粒进行样品处理的组合物、方法和系统
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN115028715B (zh) * 2022-06-23 2023-08-18 生工生物工程（上海）股份有限公司 一种抗新型冠状病毒的抗体或其抗原结合片段、试剂盒及应用
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) * 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO2005018538A2 (en) 2003-06-04 2005-03-03 Vaxim, Inc. Severe acute respiratory syndrome (sars) polypeptides, antibodies to sars polypeptides and the use thereof in diagnostic, vaccination and therapeutic applications
WO2005047459A2 (en) * 2003-08-04 2005-05-26 University Of Massachusetts Sars nucleic acids, proteins, antibodies, and uses thereof
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
CA2548942C (en) 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
US20070116716A1 (en) 2003-12-10 2007-05-24 Shuo Shen Sars coronavirus s proteins and uses thereof
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023518312A (ja) * 2020-03-22 2023-04-28 クアドルセプト バイオ リミテッド ウイルス株の進化のための多量体
US12590124B2 (en) 2020-07-16 2026-03-31 Caregen Co, Ltd. Peptide with neutralizing activity against severe acute respiratory syndrome coronavirus 2
WO2022015069A1 (ko) * 2020-07-16 2022-01-20 (주)케어젠 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드
JP2023536737A (ja) * 2020-08-04 2023-08-29 アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー Ｓａｒｓ－ｃｏｖ－２を検出するためのアッセイ
JP7813771B2 (ja) 2020-08-04 2026-02-13 アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー Ｓａｒｓ－ｃｏｖ－２を検出するためのアッセイ
WO2022044573A1 (ja) 2020-08-26 2022-03-03 国立大学法人熊本大学 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片
JP7813293B2 (ja) 2020-10-05 2026-02-12 アルピ・ロジャース コロナウイルス治療法
JP2023544910A (ja) * 2020-10-05 2023-10-25 アルピ・ロジャース コロナウイルス治療法
KR102437114B1 (ko) 2020-10-21 2022-08-26 재단법인 바이오나노헬스가드연구단 스트렙트아비딘 결합 펩타이드가 태그된 중증급성호흡기증후군 코로나바이러스 특이적 항원 및 이의 용도
KR20220052645A (ko) * 2020-10-21 2022-04-28 재단법인 바이오나노헬스가드연구단 스트렙트아비딘 결합 펩타이드가 태그된 중증급성호흡기증후군 코로나바이러스 특이적 항원 및 이의 용도
JP7747353B2 (ja) 2021-01-05 2025-10-01 センター フォー エクセレンス イン モレキュラー セル サイエンス，チャイニーズ アカデミー オブ サイエンシーズ 抗コロナウイルス完全ヒト広域スペクトル中和抗体７６ｅ１及びその適用
JP2024502347A (ja) * 2021-01-05 2024-01-18 センター フォー エクセレンス イン モレキュラー セル サイエンス，チャイニーズ アカデミー オブ サイエンシーズ 抗コロナウイルス完全ヒト広域スペクトル中和抗体７６ｅ１及びその適用
JP2025507227A (ja) * 2021-10-01 2025-03-14 エターニヴァックス バイオメディカル，インコーポレーテッド 新型コロナウイルスｓ２タンパク質のｈｒ領域に由来する組換え融合タンパク質およびその使用

Also Published As

Publication number Publication date
EP2035454A2 (en) 2009-03-18
WO2008060331A9 (en) 2008-11-20
AU2007320075A1 (en) 2008-05-22
CA2652728A1 (en) 2008-05-22
WO2008060331A2 (en) 2008-05-22
US7728110B2 (en) 2010-06-01
US20080248043A1 (en) 2008-10-09
WO2008060331A3 (en) 2008-10-02
AU2007320075A2 (en) 2009-06-11
MX2008014710A (es) 2009-02-12

Similar Documents

Publication Publication Date Title
US7728110B2 (en) Antibodies to SARS coronavirus
US7807159B2 (en) Antibodies to myostatin
JP5638804B2 (ja) ＥｒｂＢ２に対する抗体
ES2327830T3 (es) Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JP6423024B2 (ja) ＭＡｄＣＡＭに対する抗体
JP2005510201A (ja) Ｈｉｖ−１に対する中和ヒトモノクローナル抗体、それらの産生および使用
AU2018275231B2 (en) Anti-jagged1 antigen binding proteins
WO2023094980A1 (en) Antibodies to coronavirus
WO2025022303A1 (en) Antibodies against covid-19 and other human coronaviruses
WO2025120444A1 (en) An antibody-based strategy targeting activated oncogenic erg in prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100521

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20111012